Skip to main content
main-content

26.06.2019 | CART and Immunotherapy (M Ruella and P Hanley, Section Editors) | Ausgabe 4/2019 Open Access

Current Hematologic Malignancy Reports 4/2019

Induced Pluripotent Stem Cell (iPSC)–Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges

Zeitschrift:
Current Hematologic Malignancy Reports > Ausgabe 4/2019
Autoren:
Alexandros Nianias, Maria Themeli
Wichtige Hinweise
This article is part of the Topical Collection on CART and Immunotherapy

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Purpose of Review

In the rapidly developing field of adoptive cell immunotherapy, there is urgent need for discoveries that would improve outcomes, extend the applicability, and reduce the costs. Induced pluripotent stem cells (iPSC) can be a source of broadly applicable cellular immunotherapeutics, which have been manufactured, validated, and banked in advance, and can be applied across HLA barriers. Here, we discuss the recent advances and challenges in the generation of iPSC-derived cellular products for cancer therapy.

Recent Findings

iPSCs can be differentiated to functional tumor-specific T and NK cells in vitro with demonstrable in vitro and in vivo anti-tumor activity. Genetic modifications employed at the iPSC level can deliver desirable immunotherapeutic attributes to the generated immune effectors. iPSC-NK cells are currently evaluated in a clinical setting and pre-clinical testing of iPSC-T cells shows promising results but their production seems more challenging.

Summary

The use of iPSCs for the generation of tumor-targeting T/NK cells constitutes a feasible strategy to overcome limitations in manufacturing, efficacy, and applicability of cellular therapeutics.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

e.Med Onkologie

Kombi-Abonnement

Mit e.Med Onkologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Onkologie, den Premium-Inhalten der onkologischen Fachzeitschriften, inklusive einer gedruckten onkologischen Zeitschrift Ihrer Wahl.

Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2019

Current Hematologic Malignancy Reports 4/2019 Zur Ausgabe

Chronic Myeloid Leukemias (M Mauro, Section Editor)

Is There a Role for Dose Modification of TKI Therapy in CML?

CART and Immunotherapy (M Ruella and P Hanley, Section Editors)

Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era

CART and Immunotherapy (M Ruella and P Hanley, Section Editors)

Overcoming Challenges in Process Development of Cellular Therapies

B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)

Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly

CART and Immunotherapy (M Ruella and P Hanley, Section Editors)

Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise